How much do you agree with the following statements? *

	Strongly disagree	Disagree	Slightly disagree	Neither	Slightly agree	Agree	Strongly agree
The activity presented balanced, evidence-based content free of commercial bias.	The activity presented balanced, evidence-based content free of commercial bias. - Strongly disagree	The activity presented balanced, evidence-based content free of commercial bias. - Disagree	The activity presented balanced, evidence-based content free of commercial bias. - Slightly disagree	The activity presented balanced, evidence-based content free of commercial bias. - Neither	The activity presented balanced, evidence-based content free of commercial bias. - Slightly agree	The activity presented balanced, evidence-based content free of commercial bias. - Agree	The activity presented balanced, evidence-based content free of commercial bias. - Strongly agree
The presenter(s) used an effective teaching strategy.	The presenter(s) used an effective teaching strategy. - Strongly disagree	The presenter(s) used an effective teaching strategy. - Disagree	The presenter(s) used an effective teaching strategy. - Slightly disagree	The presenter(s) used an effective teaching strategy. - Neither	The presenter(s) used an effective teaching strategy. - Slightly agree	The presenter(s) used an effective teaching strategy. - Agree	The presenter(s) used an effective teaching strategy. - Strongly agree
The presentation slides / digital materials / resources and handouts were high quality.	The presentation slides / digital materials / resources and handouts were high quality. - Strongly disagree	The presentation slides / digital materials / resources and handouts were high quality. - Disagree	The presentation slides / digital materials / resources and handouts were high quality. - Slightly disagree	The presentation slides / digital materials / resources and handouts were high quality. - Neither	The presentation slides / digital materials / resources and handouts were high quality. - Slightly agree	The presentation slides / digital materials / resources and handouts were high quality. - Agree	The presentation slides / digital materials / resources and handouts were high quality. - Strongly agree
The content was relevant to / useful for my professional practice.	The content was relevant to / useful for my professional practice. - Strongly disagree	The content was relevant to / useful for my professional practice. - Disagree	The content was relevant to / useful for my professional practice. - Slightly disagree	The content was relevant to / useful for my professional practice. - Neither	The content was relevant to / useful for my professional practice. - Slightly agree	The content was relevant to / useful for my professional practice. - Agree	The content was relevant to / useful for my professional practice. - Strongly agree
The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care.	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Strongly disagree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Disagree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Slightly disagree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Neither	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Slightly agree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Agree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Strongly agree
The overall quality of the educational activity was excellent.	The overall quality of the educational activity was excellent. - Strongly disagree	The overall quality of the educational activity was excellent. - Disagree	The overall quality of the educational activity was excellent. - Slightly disagree	The overall quality of the educational activity was excellent. - Neither	The overall quality of the educational activity was excellent. - Slightly agree	The overall quality of the educational activity was excellent. - Agree	The overall quality of the educational activity was excellent. - Strongly agree

The activity successfully achieved its learning objectives by enhancing my ability to: *

	Strongly disagree	Disagree	Slightly disagree	Neither	Slightly agree	Agree	Strongly agree
Define Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and explain the rationale for the recent change in nomenclature.	Define Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and explain the rationale for the recent change in nomenclature. - Strongly disagree	Define Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and explain the rationale for the recent change in nomenclature. - Disagree	Define Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and explain the rationale for the recent change in nomenclature. - Slightly disagree	Define Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and explain the rationale for the recent change in nomenclature. - Neither	Define Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and explain the rationale for the recent change in nomenclature. - Slightly agree	Define Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and explain the rationale for the recent change in nomenclature. - Agree	Define Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and explain the rationale for the recent change in nomenclature. - Strongly agree
Describe the primary health risks associated with MASLD, including its impact on cardiovascular health, metabolic syndrome, and cancer risk.	Describe the primary health risks associated with MASLD, including its impact on cardiovascular health, metabolic syndrome, and cancer risk. - Strongly disagree	Describe the primary health risks associated with MASLD, including its impact on cardiovascular health, metabolic syndrome, and cancer risk. - Disagree	Describe the primary health risks associated with MASLD, including its impact on cardiovascular health, metabolic syndrome, and cancer risk. - Slightly disagree	Describe the primary health risks associated with MASLD, including its impact on cardiovascular health, metabolic syndrome, and cancer risk. - Neither	Describe the primary health risks associated with MASLD, including its impact on cardiovascular health, metabolic syndrome, and cancer risk. - Slightly agree	Describe the primary health risks associated with MASLD, including its impact on cardiovascular health, metabolic syndrome, and cancer risk. - Agree	Describe the primary health risks associated with MASLD, including its impact on cardiovascular health, metabolic syndrome, and cancer risk. - Strongly agree
Identify the appropriate patient populations for MASLD screening and utilize non-invasive tests like the FIB-4 index to risk-stratify patients for advanced fibrosis.	Identify the appropriate patient populations for MASLD screening and utilize non-invasive tests like the FIB-4 index to risk-stratify patients for advanced fibrosis. - Strongly disagree	Identify the appropriate patient populations for MASLD screening and utilize non-invasive tests like the FIB-4 index to risk-stratify patients for advanced fibrosis. - Disagree	Identify the appropriate patient populations for MASLD screening and utilize non-invasive tests like the FIB-4 index to risk-stratify patients for advanced fibrosis. - Slightly disagree	Identify the appropriate patient populations for MASLD screening and utilize non-invasive tests like the FIB-4 index to risk-stratify patients for advanced fibrosis. - Neither	Identify the appropriate patient populations for MASLD screening and utilize non-invasive tests like the FIB-4 index to risk-stratify patients for advanced fibrosis. - Slightly agree	Identify the appropriate patient populations for MASLD screening and utilize non-invasive tests like the FIB-4 index to risk-stratify patients for advanced fibrosis. - Agree	Identify the appropriate patient populations for MASLD screening and utilize non-invasive tests like the FIB-4 index to risk-stratify patients for advanced fibrosis. - Strongly agree
Explain the foundational role of lifestyle modifications, specifically the degree of weight loss required to improve steatosis, inflammation, and fibrosis.	Explain the foundational role of lifestyle modifications, specifically the degree of weight loss required to improve steatosis, inflammation, and fibrosis. - Strongly disagree	Explain the foundational role of lifestyle modifications, specifically the degree of weight loss required to improve steatosis, inflammation, and fibrosis. - Disagree	Explain the foundational role of lifestyle modifications, specifically the degree of weight loss required to improve steatosis, inflammation, and fibrosis. - Slightly disagree	Explain the foundational role of lifestyle modifications, specifically the degree of weight loss required to improve steatosis, inflammation, and fibrosis. - Neither	Explain the foundational role of lifestyle modifications, specifically the degree of weight loss required to improve steatosis, inflammation, and fibrosis. - Slightly agree	Explain the foundational role of lifestyle modifications, specifically the degree of weight loss required to improve steatosis, inflammation, and fibrosis. - Agree	Explain the foundational role of lifestyle modifications, specifically the degree of weight loss required to improve steatosis, inflammation, and fibrosis. - Strongly agree
Compare the mechanisms of action, indications, and clinical benefits of newly approved pharmacotherapies for MASH, including resmetirom and semaglutide.	Compare the mechanisms of action, indications, and clinical benefits of newly approved pharmacotherapies for MASH, including resmetirom and semaglutide. - Strongly disagree	Compare the mechanisms of action, indications, and clinical benefits of newly approved pharmacotherapies for MASH, including resmetirom and semaglutide. - Disagree	Compare the mechanisms of action, indications, and clinical benefits of newly approved pharmacotherapies for MASH, including resmetirom and semaglutide. - Slightly disagree	Compare the mechanisms of action, indications, and clinical benefits of newly approved pharmacotherapies for MASH, including resmetirom and semaglutide. - Neither	Compare the mechanisms of action, indications, and clinical benefits of newly approved pharmacotherapies for MASH, including resmetirom and semaglutide. - Slightly agree	Compare the mechanisms of action, indications, and clinical benefits of newly approved pharmacotherapies for MASH, including resmetirom and semaglutide. - Agree	Compare the mechanisms of action, indications, and clinical benefits of newly approved pharmacotherapies for MASH, including resmetirom and semaglutide. - Strongly agree
Discuss the emerging therapeutic landscape for MASH and the potential role of next-generation agents in managing the disease.	Discuss the emerging therapeutic landscape for MASH and the potential role of next-generation agents in managing the disease. - Strongly disagree	Discuss the emerging therapeutic landscape for MASH and the potential role of next-generation agents in managing the disease. - Disagree	Discuss the emerging therapeutic landscape for MASH and the potential role of next-generation agents in managing the disease. - Slightly disagree	Discuss the emerging therapeutic landscape for MASH and the potential role of next-generation agents in managing the disease. - Neither	Discuss the emerging therapeutic landscape for MASH and the potential role of next-generation agents in managing the disease. - Slightly agree	Discuss the emerging therapeutic landscape for MASH and the potential role of next-generation agents in managing the disease. - Agree	Discuss the emerging therapeutic landscape for MASH and the potential role of next-generation agents in managing the disease. - Strongly agree

What do you anticipate changing or how will you apply what you learned in your professional practice? *

How will you apply what you learned when working with providers of other disciplines or members of your interprofessional healthcare team? *

What barriers, if any, do you see to implementing these changes? *

Please provide feedback on your experience navigating this website and completing the CE process. *

Based on your educational needs, what topics would you like to see addressed in future educational activities? *

Please discuss any additional concerns or comments about this program and indicate whether the program met your expectations. *

attestation checkbox *

I completed this educational activity independently and in its entirety.

Leave this field blank